Acadia Pharmaceuticals (ACAD) PT Set at $50.00 by JPMorgan Chase

JPMorgan Chase set a $50.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD) in a research report report published on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of Acadia Pharmaceuticals from a hold rating to a buy rating in a research report on Saturday, February 17th. Zacks Investment Research cut shares of Acadia Pharmaceuticals from a buy rating to a hold rating in a research report on Monday, January 15th. Finally, ValuEngine cut shares of Acadia Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, March 23rd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $49.50.

NASDAQ ACAD opened at $19.29 on Tuesday. Acadia Pharmaceuticals has a 12 month low of $15.74 and a 12 month high of $41.20.



Acadia Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.03. The company had revenue of $43.56 million for the quarter, compared to analysts’ expectations of $45.30 million. Acadia Pharmaceuticals had a negative net margin of 231.71% and a negative return on equity of 73.02%. sell-side analysts expect that Acadia Pharmaceuticals will post -1.82 earnings per share for the current year.

In other Acadia Pharmaceuticals news, Director Daniel B. Soland bought 7,000 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was purchased at an average cost of $23.91 per share, with a total value of $167,370.00. Following the completion of the acquisition, the director now owns 2,000 shares in the company, valued at approximately $47,820. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Glenn Baity sold 36,558 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $32.39, for a total transaction of $1,184,113.62. Following the completion of the transaction, the executive vice president now directly owns 83,734 shares of the company’s stock, valued at $2,712,144.26. The disclosure for this sale can be found here. Company insiders own 22.25% of the company’s stock.

Several hedge funds have recently bought and sold shares of ACAD. BlackRock Inc. grew its holdings in shares of Acadia Pharmaceuticals by 5.0% in the fourth quarter. BlackRock Inc. now owns 6,710,697 shares of the biopharmaceutical company’s stock valued at $202,060,000 after purchasing an additional 321,950 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Acadia Pharmaceuticals by 25.8% in the fourth quarter. First Trust Advisors LP now owns 1,523,112 shares of the biopharmaceutical company’s stock valued at $45,861,000 after purchasing an additional 312,671 shares in the last quarter. Sectoral Asset Management Inc grew its holdings in shares of Acadia Pharmaceuticals by 37.6% in the fourth quarter. Sectoral Asset Management Inc now owns 1,131,722 shares of the biopharmaceutical company’s stock valued at $34,076,000 after purchasing an additional 309,330 shares in the last quarter. Tekla Capital Management LLC purchased a new position in shares of Acadia Pharmaceuticals in the fourth quarter valued at $7,404,000. Finally, Wealthstreet Investment Advisors LLC purchased a new position in shares of Acadia Pharmaceuticals in the fourth quarter valued at $6,036,000. 96.24% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://dakotafinancialnews.com/2018/04/13/acadia-pharmaceuticals-acad-pt-set-at-50-00-by-jpmorgan-chase.html.

Acadia Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Analyst Recommendations for Acadia Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for Acadia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply